Text Size

Pilot Study of Human Tear Proteins

This study has been terminated.
(Stopped due to low enrollment)
Sponsor:
Information provided by (Responsible Party):
University of Colorado, Denver
ClinicalTrials.gov Identifier:
NCT00453258
First received: March 26, 2007
Last updated: January 15, 2013
Last verified: October 2012
History of Changes
  Purpose

The significance of our study is in the importance of understanding the quality and quantity of proteins in the human tear film from diseased and non-diseased patients. This pilot study will provide data to plan prospective research to better delineate the utility of tear proteins in diagnosing and following disease status in a non-invasive fashion.


Condition Intervention
Eye Disease
 Other: Eye Examination

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Analysis of Human Tear Proteins: A Pilot Study to Describe the Tear Film Proteome of Patients Undergoing Ophthalmic Examination.

Resource links provided by NLM:

MedlinePlus related topics: Eye Diseases
U.S. FDA Resources

Further study details as provided by University of Colorado, Denver:

Primary Outcome Measures:
  • Plan Prospective Research [ Time Frame: Throughout study participation ] [ Designated as safety issue: No ]
    Pilot study will provide data to plan prospective research to better delineate the utility of tear proteins in diagnosing and following disease status in a non-invasive fashion.


Enrollment: 63
Study Start Date: February 2007
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Study Subject
Subjects receiving eye examination
 Other: Eye Examination
Subjects receiving eye examination

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Subjects receiving eye examination

Criteria

Inclusion Criteria:

  • 18 years of age and older
  • able to cooperate with tear sample collection
  • provide written informed consent

Exclusion Criteria:

  • special populations (children, pregnant or lactating females, prisoners, etc)
  • refusal to sign sudy consent
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00453258

Locations
United States, Colorado
Rocky Mountain Lions Eye Institute
Aurora, Colorado, United States, 80045
Sponsors and Collaborators
University of Colorado, Denver
Investigators
Principal Investigator: Malik Y. Kahook, MD Rocky Mountain Lions Eye Institute
  More Information

No publications provided

Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT00453258     History of Changes
Other Study ID Numbers: 06-0862
Study First Received: March 26, 2007
Last Updated: January 15, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by University of Colorado, Denver:
ocular proteomics
eye disease
proteomics

Additional relevant MeSH terms:
Eye Diseases

ClinicalTrials.gov processed this record on June 18, 2013